News | Cardiovascular Ultrasound | July 20, 2017

3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk

Inexpensive and radiation-free technology has potential to become key screening tool for identifying at-risk individuals

3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk

July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as three-dimensional vascular ultrasound (3DVUS) estimated the quantification of plaque burden (in cubic millimeters) as an important addition to conventional risk factor profile in addressing patient risk stratification.

At an average age of 45 years, they found the plaque burden in subjects was more than twice as high in men as in women (63.4 cubic millimeters vs. 25.7), and higher in the femoral arteries, and with increasing age.

The study was published online in The Journal of the American College of Cardiology.   

Researchers explored the bilateral carotid and femoral arteries of 3,860 middle aged participants without prior cardiovascular disease who were employees of the Banco de Santander in Madrid, Spain. This is an ongoing observational prospective cohort study where participants are being followed up for 10 years. The 3DVUS examinations were performed using a new Phillips iU22 ultrasound system equipped with a VL13-5 3D volume–linear array transducer. This equipment will be available in the near future for routine patient care.

The clinical application of 3DVUS techniques is still at the research and development stage, but there are now a number of clinically promising areas including the measurement of plaque. Direct quantification of atherosclerotic plaque volume by 3DVUS is more reproducible than two-dimensional techniques.

“3DVUS is a feasible, reproducible, and novel imaging technique for quantifying early carotid and femoral atherosclerotic burden in large populations,” said the study’s lead author, Valentin Fuster, M.D., Ph.D., director of Mount Sinai Heart and physician-in-chief of The Mount Sinai Hospital. “This novel method is valid for imaging superficial peripheral atherosclerosis burden from early to advanced stages of disease and can be applied to identification of individuals at risk, targeting or monitoring treatment. Further studies are needed, however, to assess the cost utility of this method compared with others when used in large-scale practice settings and population-based epidemiological studies.”

The study is part of an international initiative that is being conducted through partnerships with the National Center for Cardiovascular Research in Spain, the Icahn School of Medicine at Mount Sinai, and the Framingham Heart Study.

For more information: www.mountsinai.org

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Clarius Wireless Ultrasound Scanners Now Available With Advanced Features
News | Ultrasound Imaging| August 09, 2017
Clarius Mobile Health has released advanced features and options for its wireless handheld ultrasound scanner for...
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init